Skip to main content

Pfizer data boosts hopes children will soon be eligible for COVID-19 vaccine, and CDC expands booster program

There was good news for parents Friday when Pfizer said the vaccine it developed with German partner BioNTech proved 90.7% effective in preventing symptomatic COVID-19 in children aged 5 to 11 in a clinical trial, using a 10 mg dose instead of the 30 mg given to adults.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.